Cancer Grand Challenges
@cancergrand.bsky.social
Daring to solve some of the most complex challenges in cancer research | Founded by Cancer Research UK & The NCI
https://www.cancergrandchallenges.org/
https://www.cancergrandchallenges.org/
📢 New Impact Report from SPECIFICANCER, the team unravelling one of cancer biology’s hardest puzzles: tissue specificity.
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
December 8, 2025 at 3:38 PM
📢 New Impact Report from SPECIFICANCER, the team unravelling one of cancer biology’s hardest puzzles: tissue specificity.
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
A huge thank you to the team and thanks to our co-funders, @themarkfdn.bsky.social and @cancerresearchuk.org for supporting global science.
🔗 lnkd.in/dQC-iHmK
What if we could spot #cancer before it strikes — or while it’s still treatable? A new study published in
@rsnasky.bsky.social is bringing us a step closer to that goal.
🔗 Read more doi.org/10.1148/radi...
Congratulations to Joseph Lo, Shelley Hwang and the #CancerGrandChallenges PRECISION team.
@rsnasky.bsky.social is bringing us a step closer to that goal.
🔗 Read more doi.org/10.1148/radi...
Congratulations to Joseph Lo, Shelley Hwang and the #CancerGrandChallenges PRECISION team.
Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in SituRadiology
Mammographic radiomic features were able to predict occult invasive disease in core-needle biopsy–proven ductal carcinoma in situ in patients from three countries.
doi.org
December 3, 2025 at 2:09 PM
What if we could spot #cancer before it strikes — or while it’s still treatable? A new study published in
@rsnasky.bsky.social is bringing us a step closer to that goal.
🔗 Read more doi.org/10.1148/radi...
Congratulations to Joseph Lo, Shelley Hwang and the #CancerGrandChallenges PRECISION team.
@rsnasky.bsky.social is bringing us a step closer to that goal.
🔗 Read more doi.org/10.1148/radi...
Congratulations to Joseph Lo, Shelley Hwang and the #CancerGrandChallenges PRECISION team.
Read the newly published impact report from the SPECIFICANCER team that reshaped our understanding of tissue specificity.
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
December 1, 2025 at 4:48 PM
Read the newly published impact report from the SPECIFICANCER team that reshaped our understanding of tissue specificity.
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
Thanks to our co-funders, @themarkfdn.bsky.social, for supporting the #CancerGrandChallenges team and global science.
🔗 lnkd.in/eDrQ9guu
Register today to join the conversation that reframes cancer from being about the tumour to being about the host-tumour dialogue.
📝 Register today
🗓️ 17–19 June 2026
📍 The Royal Society, London
🔗 lnkd.in/ejup_Wbj
📝 Register today
🗓️ 17–19 June 2026
📍 The Royal Society, London
🔗 lnkd.in/ejup_Wbj
December 1, 2025 at 11:38 AM
Register today to join the conversation that reframes cancer from being about the tumour to being about the host-tumour dialogue.
📝 Register today
🗓️ 17–19 June 2026
📍 The Royal Society, London
🔗 lnkd.in/ejup_Wbj
📝 Register today
🗓️ 17–19 June 2026
📍 The Royal Society, London
🔗 lnkd.in/ejup_Wbj
Explore how cancer research can prepare to unlock the full potential of data-driven innovation at the Cancer Research UK upcoming Data-driven cancer research conference in Edinburgh from 24-26 February 2026.
Standard rate ticket registration closes 9 January 2026.
🎟️ Register now: cruk.ink/48aRoi0
Standard rate ticket registration closes 9 January 2026.
🎟️ Register now: cruk.ink/48aRoi0
November 28, 2025 at 10:15 AM
Explore how cancer research can prepare to unlock the full potential of data-driven innovation at the Cancer Research UK upcoming Data-driven cancer research conference in Edinburgh from 24-26 February 2026.
Standard rate ticket registration closes 9 January 2026.
🎟️ Register now: cruk.ink/48aRoi0
Standard rate ticket registration closes 9 January 2026.
🎟️ Register now: cruk.ink/48aRoi0
🧬 Sponsor the #CancerGrandChallenges Spatial biology conference and join the community redefining how we see cancer.
Help accelerate the next generation of spatial approaches that could revolutionise cancer diagnosis and treatment.
Find out more: lnkd.in/e-7iZF6d
Help accelerate the next generation of spatial approaches that could revolutionise cancer diagnosis and treatment.
Find out more: lnkd.in/e-7iZF6d
November 25, 2025 at 3:48 PM
🧬 Sponsor the #CancerGrandChallenges Spatial biology conference and join the community redefining how we see cancer.
Help accelerate the next generation of spatial approaches that could revolutionise cancer diagnosis and treatment.
Find out more: lnkd.in/e-7iZF6d
Help accelerate the next generation of spatial approaches that could revolutionise cancer diagnosis and treatment.
Find out more: lnkd.in/e-7iZF6d
The new paper from SPECIFICANCER, published in
@natureportfolio.nature.com reveals that it’s not just the mutation that matters — it’s where in the liver that mutation appears.
Congratulations to the team (co-funded by
@themarkfdn.bsky.social). 👉 Read more: lnkd.in/eTVh9YY6
@natureportfolio.nature.com reveals that it’s not just the mutation that matters — it’s where in the liver that mutation appears.
Congratulations to the team (co-funded by
@themarkfdn.bsky.social). 👉 Read more: lnkd.in/eTVh9YY6
November 20, 2025 at 1:40 PM
The new paper from SPECIFICANCER, published in
@natureportfolio.nature.com reveals that it’s not just the mutation that matters — it’s where in the liver that mutation appears.
Congratulations to the team (co-funded by
@themarkfdn.bsky.social). 👉 Read more: lnkd.in/eTVh9YY6
@natureportfolio.nature.com reveals that it’s not just the mutation that matters — it’s where in the liver that mutation appears.
Congratulations to the team (co-funded by
@themarkfdn.bsky.social). 👉 Read more: lnkd.in/eTVh9YY6
🎉 Congratulations to @kinglhung.bsky.social from team eDyNAmiC for receiving the prestigious prize and for having his essay, “Oncogenes out of context: Cancer genes break free from the regulatory constraints of chromosomes”, published in
@science.org.
📖 Read more - lnkd.in/ekMqXC6J
@science.org.
📖 Read more - lnkd.in/ekMqXC6J
Honored to receive the Science & SciLifeLab Prize! Very grateful to all my mentors and colleagues. I wrote an article in @science.org about my PhD thesis research on extrachromosomal DNA at Stanford @stanfordmedicine.bsky.social. www.science.org/doi/10.1126/...
November 18, 2025 at 4:09 PM
🎉 Congratulations to @kinglhung.bsky.social from team eDyNAmiC for receiving the prestigious prize and for having his essay, “Oncogenes out of context: Cancer genes break free from the regulatory constraints of chromosomes”, published in
@science.org.
📖 Read more - lnkd.in/ekMqXC6J
@science.org.
📖 Read more - lnkd.in/ekMqXC6J
We’re proud to share that 25 individuals from our international #CancerGrandChallenges community have been named among the @clarivate.com #highlycited2025.
To every awardee across our community congratulations, and thank you for your leadership and impact 👏. Read more ow.ly/y23050XohmV
To every awardee across our community congratulations, and thank you for your leadership and impact 👏. Read more ow.ly/y23050XohmV
Clarivate Highly Cited Researchers 2025
The Highly Cited Researchers 2025 list identifies and celebrates individuals who have demonstrated significant and broad influence in their fields of research. Through rigorous selection criteria and ...
ow.ly
November 17, 2025 at 1:37 PM
We’re proud to share that 25 individuals from our international #CancerGrandChallenges community have been named among the @clarivate.com #highlycited2025.
To every awardee across our community congratulations, and thank you for your leadership and impact 👏. Read more ow.ly/y23050XohmV
To every awardee across our community congratulations, and thank you for your leadership and impact 👏. Read more ow.ly/y23050XohmV
That’s a wrap for Future Leaders' Conference 2025!
This conference wasn’t just about sharing what’s been done—it was about igniting what comes next. The optimism and connections we witnessed will drive real progress in tackling some of the hardest questions in cancer #FLC25 #CancerGrandChallenges
This conference wasn’t just about sharing what’s been done—it was about igniting what comes next. The optimism and connections we witnessed will drive real progress in tackling some of the hardest questions in cancer #FLC25 #CancerGrandChallenges
November 14, 2025 at 5:08 PM
That’s a wrap for Future Leaders' Conference 2025!
This conference wasn’t just about sharing what’s been done—it was about igniting what comes next. The optimism and connections we witnessed will drive real progress in tackling some of the hardest questions in cancer #FLC25 #CancerGrandChallenges
This conference wasn’t just about sharing what’s been done—it was about igniting what comes next. The optimism and connections we witnessed will drive real progress in tackling some of the hardest questions in cancer #FLC25 #CancerGrandChallenges
🔬 New research from #CancerGrandChallenges team PROSPECT explores possible links between diet and risk of bowel polyps in younger women.
🔗 Read more www.cancergrandchallenges.org/news/an-asso...
🔗 Read more www.cancergrandchallenges.org/news/an-asso...
November 13, 2025 at 4:30 PM
🔬 New research from #CancerGrandChallenges team PROSPECT explores possible links between diet and risk of bowel polyps in younger women.
🔗 Read more www.cancergrandchallenges.org/news/an-asso...
🔗 Read more www.cancergrandchallenges.org/news/an-asso...
“Take the most exciting options, take risks and be bold”
Words from Karen Vousden, Principal Group Leader at @crick.ac.uk and #CancerGrandChallenges Scientific Committee member, at day one of our Future Leaders’ Conference 2025 #FLC25
Words from Karen Vousden, Principal Group Leader at @crick.ac.uk and #CancerGrandChallenges Scientific Committee member, at day one of our Future Leaders’ Conference 2025 #FLC25
November 12, 2025 at 5:51 PM
“Take the most exciting options, take risks and be bold”
Words from Karen Vousden, Principal Group Leader at @crick.ac.uk and #CancerGrandChallenges Scientific Committee member, at day one of our Future Leaders’ Conference 2025 #FLC25
Words from Karen Vousden, Principal Group Leader at @crick.ac.uk and #CancerGrandChallenges Scientific Committee member, at day one of our Future Leaders’ Conference 2025 #FLC25
Members of NexTGen (co-funded by @themarkfdn.bsky.social), Nikolaos Sgourakis & John Maris, contributed to a new Nature paper from David Baker’s lab showing AI-designed antibodies with atomic-level precision
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
Atomically accurate de novo design of antibodies with RFdiffusion - Nature
The combination of computational design, laboratory-based screening and biophysical validation enables the de novo generation of variable heavy-chain antibody fragments and antibodies that precis...
nature.com
November 11, 2025 at 12:39 PM
Members of NexTGen (co-funded by @themarkfdn.bsky.social), Nikolaos Sgourakis & John Maris, contributed to a new Nature paper from David Baker’s lab showing AI-designed antibodies with atomic-level precision
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
A potential game-changer 👉
nature.com/articles/s41586-025-09721-5
We’re shifting how we think about cancer. Join the conversation that reframes cancer from being about the tumour to being about the host-tumour dialogue.
📝 Registration opens Monday 1 December
🗓️ 17–19 June 2026
📍The Royal Society, London
🔗 cancergrandchallenges.org/conferences/cancer-and-the-host
📝 Registration opens Monday 1 December
🗓️ 17–19 June 2026
📍The Royal Society, London
🔗 cancergrandchallenges.org/conferences/cancer-and-the-host
November 10, 2025 at 12:10 PM
We’re shifting how we think about cancer. Join the conversation that reframes cancer from being about the tumour to being about the host-tumour dialogue.
📝 Registration opens Monday 1 December
🗓️ 17–19 June 2026
📍The Royal Society, London
🔗 cancergrandchallenges.org/conferences/cancer-and-the-host
📝 Registration opens Monday 1 December
🗓️ 17–19 June 2026
📍The Royal Society, London
🔗 cancergrandchallenges.org/conferences/cancer-and-the-host
Great to hear Iain Foulkes join @break-cancer.bsky.social's @boehmjesse.bsky.social, @su2c.bsky.social's Julian Adams & NUT Carcinoma Alliance's Maddie Musselman at @milkeninstitute.org #MIHealthSummit to discuss how global collaboration can drive innovation in cancer research #CancerGrandChallenges
November 7, 2025 at 3:49 PM
Great to hear Iain Foulkes join @break-cancer.bsky.social's @boehmjesse.bsky.social, @su2c.bsky.social's Julian Adams & NUT Carcinoma Alliance's Maddie Musselman at @milkeninstitute.org #MIHealthSummit to discuss how global collaboration can drive innovation in cancer research #CancerGrandChallenges
💡 New research from the #CancerGrandChallenges NexTGen team offers a way to make CAR T-cell therapy more effective — even against cancers that try to hide.
📖 Read the open-access paper in Nature Cancer: doi.org/10.1038/s43018-025-01056-4
#Immunotherapy #CART #PaediatricOncology #CancerResearch
📖 Read the open-access paper in Nature Cancer: doi.org/10.1038/s43018-025-01056-4
#Immunotherapy #CART #PaediatricOncology #CancerResearch
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy - Nature Cancer
Majzner and colleagues show that engineering T cells with a membrane-tethered version of the signaling adaptor molecule SLP-76 alongside a chimeric antigen receptor (CAR) enhances CAR T cell activity ...
doi.org
November 7, 2025 at 2:12 PM
💡 New research from the #CancerGrandChallenges NexTGen team offers a way to make CAR T-cell therapy more effective — even against cancers that try to hide.
📖 Read the open-access paper in Nature Cancer: doi.org/10.1038/s43018-025-01056-4
#Immunotherapy #CART #PaediatricOncology #CancerResearch
📖 Read the open-access paper in Nature Cancer: doi.org/10.1038/s43018-025-01056-4
#Immunotherapy #CART #PaediatricOncology #CancerResearch
🎉 Congratulations to Sir Mike Stratton (Team Lead) and Paul Brennan (Co-Investigator) of team Mutographs who have been awarded a @erc.europa.eu Synergy grant of €10.4m to continue researching the association between early-onset colorectal cancer and the colibactin mutational signature.
Bowel cancer cases in people under 50 are rising worldwide, and the reasons remain unclear.
With a new @erc.europa.eu Synergy Grant, scientists will look into how gut bacteria in early life might increase the risk of bowel cancer in young adults. 👇
www.sanger.ac.uk/news_item/sa...
With a new @erc.europa.eu Synergy Grant, scientists will look into how gut bacteria in early life might increase the risk of bowel cancer in young adults. 👇
www.sanger.ac.uk/news_item/sa...
Sanger scientists receive major grant to study rise of early onset colorectal cancer
Dr Trevor Lawley and Professor Mike Stratton awarded funding to enable investigation into the roots of growing cancer concern.
www.sanger.ac.uk
November 6, 2025 at 3:48 PM
🎉 Congratulations to Sir Mike Stratton (Team Lead) and Paul Brennan (Co-Investigator) of team Mutographs who have been awarded a @erc.europa.eu Synergy grant of €10.4m to continue researching the association between early-onset colorectal cancer and the colibactin mutational signature.
We're so grateful to our partners at the @themarkfdn.bsky.social for supporting the NexTGen team and helping to make their research possible.
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
Team NexTGen, featured in @washingtonpost.com discussing their CAR T-cell immunotherapy trial.
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
November 4, 2025 at 9:32 AM
We're so grateful to our partners at the @themarkfdn.bsky.social for supporting the NexTGen team and helping to make their research possible.
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
Thank you to all our #CancerGrandChallenge partners who make progress possible 👏
Team NexTGen, featured in @washingtonpost.com discussing their CAR T-cell immunotherapy trial.
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
November 3, 2025 at 1:07 PM
Team NexTGen, featured in @washingtonpost.com discussing their CAR T-cell immunotherapy trial.
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
Thank you to @themarkfdn.bsky.social for supporting global science - working together to tackle one of the toughest challenges in cancer.
👉 If you have access - www.washingtonpost.com/science/2025...
Discover is here — our annual progress magazine showcasing a year of extraordinary scientific breakthroughs from across the #CancerGrandChallenges community.
👉 Read the full magazine here: www.cancergrandchallenges.org/discover-a-y...
👉 Read the full magazine here: www.cancergrandchallenges.org/discover-a-y...
October 28, 2025 at 9:43 AM
Discover is here — our annual progress magazine showcasing a year of extraordinary scientific breakthroughs from across the #CancerGrandChallenges community.
👉 Read the full magazine here: www.cancergrandchallenges.org/discover-a-y...
👉 Read the full magazine here: www.cancergrandchallenges.org/discover-a-y...
We are thrilled that Charles Swanton, Chair of the #CancerGrandChallenges Scientific Committee, has been elected to the @nam.edu.
Please join us in congratulating Charlie on this prestigious and well-deserved honour 👏 #CancerResearch #TeamScience
Please join us in congratulating Charlie on this prestigious and well-deserved honour 👏 #CancerResearch #TeamScience
Congratulations and welcome to the 100 new members elected today to the National Academy of Medicine! #NAMmtg nam.edu/news-and-ins...
nam.edu
October 23, 2025 at 3:12 PM
We are thrilled that Charles Swanton, Chair of the #CancerGrandChallenges Scientific Committee, has been elected to the @nam.edu.
Please join us in congratulating Charlie on this prestigious and well-deserved honour 👏 #CancerResearch #TeamScience
Please join us in congratulating Charlie on this prestigious and well-deserved honour 👏 #CancerResearch #TeamScience
A new @nature.com Reviews Drug Discovery article highlights the first candidate drug to combat #cachexia — a major step toward treating cachexia, a devastating condition affecting many people with cancer.
🔗 Read the full article: www.nature.com/articles/d41...
#CancerResearch
🔗 Read the full article: www.nature.com/articles/d41...
#CancerResearch
October 22, 2025 at 9:01 AM
A new @nature.com Reviews Drug Discovery article highlights the first candidate drug to combat #cachexia — a major step toward treating cachexia, a devastating condition affecting many people with cancer.
🔗 Read the full article: www.nature.com/articles/d41...
#CancerResearch
🔗 Read the full article: www.nature.com/articles/d41...
#CancerResearch
New research from team PROMINENT (@nlbigas.bsky.social), published in @nature.com, uncovers clues why men face a higher risk of bladder cancer and reveals that tobacco smoke acts as a promoter, not an initiator, in bladder cancer development.
Read more: www.cancergrandchallenges.org/news/early-c...
Read more: www.cancergrandchallenges.org/news/early-c...
October 8, 2025 at 3:15 PM
New research from team PROMINENT (@nlbigas.bsky.social), published in @nature.com, uncovers clues why men face a higher risk of bladder cancer and reveals that tobacco smoke acts as a promoter, not an initiator, in bladder cancer development.
Read more: www.cancergrandchallenges.org/news/early-c...
Read more: www.cancergrandchallenges.org/news/early-c...
“If we can stop cachexia, we can help patients live better — and longer.” - Tobias Janowitz, Co-Lead of team CANCAN.
If you have access, discover how their work could change the way we treat one of cancer’s most overlooked challenges 👉 www.thetimes.com/uk/science/a... #CancerGrandChallenges
If you have access, discover how their work could change the way we treat one of cancer’s most overlooked challenges 👉 www.thetimes.com/uk/science/a... #CancerGrandChallenges
October 7, 2025 at 9:05 AM
“If we can stop cachexia, we can help patients live better — and longer.” - Tobias Janowitz, Co-Lead of team CANCAN.
If you have access, discover how their work could change the way we treat one of cancer’s most overlooked challenges 👉 www.thetimes.com/uk/science/a... #CancerGrandChallenges
If you have access, discover how their work could change the way we treat one of cancer’s most overlooked challenges 👉 www.thetimes.com/uk/science/a... #CancerGrandChallenges
#CancerGrandChallenges IMAXT in @nature.com:
Using CloneSeq-SV, the team tracked ovarian cancer clones and found:
• Resistant clones often exist from diagnosis
• ctDNA spotted recurrence ~8 months earlier than imaging
• Actionable drivers (e.g. ERBB2) can be revealed
www.nature.com/articles/s41...
Using CloneSeq-SV, the team tracked ovarian cancer clones and found:
• Resistant clones often exist from diagnosis
• ctDNA spotted recurrence ~8 months earlier than imaging
• Actionable drivers (e.g. ERBB2) can be revealed
www.nature.com/articles/s41...
October 3, 2025 at 12:35 PM
#CancerGrandChallenges IMAXT in @nature.com:
Using CloneSeq-SV, the team tracked ovarian cancer clones and found:
• Resistant clones often exist from diagnosis
• ctDNA spotted recurrence ~8 months earlier than imaging
• Actionable drivers (e.g. ERBB2) can be revealed
www.nature.com/articles/s41...
Using CloneSeq-SV, the team tracked ovarian cancer clones and found:
• Resistant clones often exist from diagnosis
• ctDNA spotted recurrence ~8 months earlier than imaging
• Actionable drivers (e.g. ERBB2) can be revealed
www.nature.com/articles/s41...